Newamsterdam Pharma Co N.V. (NAMS)Chief Accounting Officer sold ~$3.06M
Louise Frederika Kooij, Chief Accounting Officer at Newamsterdam Pharma Co N.V., sold ~$3.06M of Newamsterdam Pharma Co N.V. shares.
- ~$3.06M
- Approx. value · 150K sh @ $20.37
- 15K
- Holds after · shares reported
- Traded
- Mar 4, 2025
- Filed
- Mar 5, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 4, 2025 · this disclosureInsiderOfficer sold ~$3.06M of NAMS shares in the open market
What came next
- Mar 4, 2025InsiderDirector purchased ~$84K of NAMS shares in the open market
- Mar 26, 2025InsiderDirector purchased ~$26K of NAMS shares in the open market
- Jun 16, 2025Insider · 2 peopleInsiders: 1 purchase (~$167K), 2 sales (~$1.9M)
- Jun 24, 2025InsiderDirector purchased ~$46K of NAMS shares in the open market
- Jun 25, 2025InsiderDirector purchased ~$23K of NAMS shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Newamsterdam Pharma Co N.V.
For Newamsterdam Pharma Co N.V., OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 6 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its NAMS page.
Other recent filings by Louise Frederika Kooij, Chief Accounting Officer
- SEC Form 4 at Newamsterdam Pharma Co N.V. (NAMS)Sep 10, 2025
- SEC Form 4 at Newamsterdam Pharma Co N.V. (NAMS)Sep 10, 2025
- SEC Form 4 at Newamsterdam Pharma Co N.V. (NAMS)Sep 5, 2025
- SEC Form 4 at Newamsterdam Pharma Co N.V. (NAMS)Aug 27, 2025
- SEC Form 4 at Newamsterdam Pharma Co N.V. (NAMS)Oct 1, 2024
The full history of Louise Frederika Kooij, Chief Accounting Officer is on the profile page.
How this filing works
Other disclosures at Newamsterdam Pharma Co N.V.
- SEC Form 4Oct 2, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its NAMS page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
